

(43) International Publication Date
7 May 2015 (07.05.2015)(10) International Publication Number
WO 2015/066188 A1

(51) International Patent Classification:

C07D 405/14 (2006.01) **C07D 403/06** (2006.01)
C07D 413/14 (2006.01) **C07D 405/04** (2006.01)
C07D 213/73 (2006.01) **C07D 409/04** (2006.01)
C07D 401/04 (2006.01) **C07D 241/20** (2006.01)
C07D 401/06 (2006.01) **A61K 31/4418** (2006.01)
C07D 401/12 (2006.01) **A61P 35/00** (2006.01)

(21) International Application Number:

PCT/US2014/062913

(22) International Filing Date:

29 October 2014 (29.10.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/898,761 1 November 2013 (01.11.2013) US
 PCT/CN2014/088409
 11 October 2014 (11.10.2014) CN

(71) Applicant (for all designated States except US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, 4056 Basel (CH).


(72) Inventors; and

(71) Applicants (for US only): **BAGDANOFF, Jeffrey T.** [US/US]; Novartis Institutes for BioMedical Research, Inc., Emeryville Site, 5300 Chiron Way, Bldg. #4, Emeryville, California 94608 (US). **DING, Yu** [CA/US]; Novartis Institutes for BioMedical Research, Inc., Emeryville Site, 5300 Chiron Way, Bldg. #4, Emeryville, California 94608 (US). **HAN, Wooseok** [KR/US]; Novartis Institutes for BioMedical Research, Inc., Emeryville Site, 5300 Chiron Way, Bldg. #4, Emeryville, California 94608 (US). **HUANG, Zilin** [CN/US]; 133 Beach Park

Blvd., Foster City, California 94404 (US). **JIANG, Qun** [CN/CN]; Suzhou Novartis Pharma Technology Co., Ltd., #18 Tonglian Road, Riverside Industrial Park, Changshu Economic Development Zone, Changshu, Jiangsu 215537 (CN). **JIN, Jeff Xianming** [US/US]; Novartis Institutes for BioMedical Research, Inc., Emeryville Site, 5300 Chiron Way, Bldg. #4, Emeryville, California 94608 (US). **KOU, Xiang** [CN/CN]; Novartis Pharmaceuticals (China), Building 8, 898 Halei Road, Pudong District, Shanghai 201203 (CN). **LEE, Patrick** [US/US]; Novartis Institutes for BioMedical Research, Inc., Emeryville Site, 5300 Chiron Way, Bldg. #4, Emeryville, California 94608 (US). **LINDVALL, Mika** [FI/US]; Novartis Institutes for BioMedical Research, Inc., Emeryville Site, 5300 Chiron Way, Bldg. #4, Emeryville, California 94608 (US). **MIN, Zhongcheng** [CN/CN]; Suzhou Novartis Pharma Technology Co., Ltd., #18 Tonglian Road, Riverside Industrial Park, Changshu Economic Development Zone, Changshu, Jiangsu 215537 (CN). **PAN, Yue** [CN/US]; Novartis Institutes for BioMedical Research, Inc., Emeryville Site, 5300 Chiron Way, Bldg. #4, Emeryville, California 94608 (US). **PECCHI, Sabina** [IT/US]; 5834 Merriewood Drive, Oakland, California 94611 (US). **PFISTER, Keith Bruce** [US/US]; Novartis Institutes for BioMedical Research, Inc., Emeryville Site, 5300 Chiron Way, Bldg. #4, Emeryville, California 94608 (US). **POON, Daniel** [US/US]; Novartis Institutes for BioMedical Research, Inc., Emeryville Site, 5300 Chiron Way, Bldg. #4, Emeryville, California 94608 (US). **RAUNIYAR, Vivek** [NP/US]; Novartis Institutes for BioMedical Research, Inc., Emeryville Site, 5300 Chiron Way, Bldg. #4, Emeryville, California 94608 (US). **WANG, Xiaojing Michael** [US/US]; Novartis Institutes for BioMedical Research, Inc., Emeryville Site, 5300 Chiron Way, Bldg. #4, Emeryville, California 94608 (US). **ZHANG,**

[Continued on next page]

(54) Title: AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS



(I)

(57) Abstract: The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.



Qiong [CN/US]; Novartis Institutes for BioMedical Research, Inc., Emeryville Site, 5300 Chiron Way, Bldg. #4, Emeryville, California 94608 (US). **ZHOU, Jianguang** [CN/CN]; Suzhou Novartis Pharma Technology Co., Ltd., #18 Tonglian Road, Riverside Industrial Park, Changshu Economic Development Zone, Changshu, Jiangsu 215537 (CN). **ZHU, Shejin** [CN/US]; Novartis Institutes for Bio-Medical Research, Inc., Emeryville Site, 5300 Chiron Way, Bldg. #4, Emeryville, California 94608 (US).

(74) **Common Representative:** **NOVARTIS AG**; Lichtstrasse 35, 4056 Basel (CH).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,

ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))